The American Cancer Society estimated that about 1.5 million new cases of cancer would be diagnosed in the United States in 2009 with cancers of the prostate and breast being the most frequently diagnosed non-dermatological cancers in men and women,
followed by lung and colorectal cancers in both men and in women. Though the prostate cancer mortality rate has been declining over the past two decades,
one in six men will still develop prostate cancer in his lifetime (1).
Methods and Materials
Utilizing a 1.5T scanner (Philips Healthcare,
The Netherlands) and a trans-rectal biopsy device (Invivo Corporation,
USA),a target lesion within the prostate gland was localized with a 5-channel cardiac surface coil with the patient in the prone position. A localizer was followed by T2 sagittals and T2 axials for the purpose of localization and targeting. Upon localization of the needle-guide,
USA) was used to determine...
The target measuring 1.7 cm in greatest dimension was successfully ablated,
sparing other structures. The feasibility of a trans-rectal approach for therapy delivery was validated and took considerably less time than a trans-perineal approach.
MRI-guided laser ablation,
using a method similar to MRI-guided trans-rectal biopsy (6),
and precise delivery of laser dose.
Minimally invasive ablative therapy for organ-confined prostate cancer is evolving as a viable option in select patient populations (7).
MR-guided trans-rectal laser therapy with real-time MR temperature imaging feedback to guide delivery appears promising as a safe and effective delivery method.
American Cancer Society, http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_prostate_cancer_36.asp ; accessed January 14,
2011 National Comprehensive Cancer Clinical Practice Guidelines in Oncology,
Prostate Cancer V.1.2008, www.nccn.org ,
accessed April 12,
Radical radiotherapy for prostate cancer is the ‘only way to go’,
Brachytherapy or surgery? A composite view,